Clearside Biomedical Inc (CLSD) concluded trading on Wednesday at a closing price of $0.58, with 226.18 million shares of worth about $131.19 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -36.56% during that period and on July 23, 2025 the price saw a gain of about 66.48%. Currently the company’s common shares owned by public are about 77.27M shares, out of which, 61.36M shares are available for trading.
Stock saw a price change of -30.02% in past 5 days and over the past one month there was a price change of -28.69%. Year-to-date (YTD), CLSD shares are showing a performance of -50.00% which decreased to -38.42% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.29 but also hit the highest price of $1.65 during that period. The average intraday trading volume for Clearside Biomedical Inc shares is 466.30K. The stock is currently trading -20.40% below its 20-day simple moving average (SMA20), while that difference is down -25.43% for SMA50 and it goes to -37.65% lower than SMA200.
Clearside Biomedical Inc (NASDAQ: CLSD) currently have 77.27M outstanding shares and institutions hold larger chunk of about 13.71% of that.
The stock has a current market capitalization of $45.46M and its 3Y-monthly beta is at 2.10. It has posted earnings per share of -$0.41 in the same period. It has Quick Ratio of 3.19. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CLSD, volatility over the week remained 63.46% while standing at 19.10% over the month.
Stock’s fiscal year EPS is expected to rise by 32.52% while it is estimated to increase by 4.95% in next year. EPS is likely to grow at an annualized rate of 23.71% for next 5-years, compared to annual growth of 10.40% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Stifel on July 18, 2025 offering a Hold rating for the stock and assigned a target price of $2 to it. On July 18, 2025, Chardan Capital Markets Downgrade their recommendations, while on August 21, 2024, Chardan Capital Markets Initiated their ratings for the stock with a price target of $6. Stock get an Outperform rating from Oppenheimer on June 25, 2024.
